1. Home
  2. FATE vs CPHC Comparison

FATE vs CPHC Comparison

Compare FATE & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • CPHC
  • Stock Information
  • Founded
  • FATE 2007
  • CPHC 1994
  • Country
  • FATE United States
  • CPHC United States
  • Employees
  • FATE N/A
  • CPHC N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • CPHC Services-Misc. Amusement & Recreation
  • Sector
  • FATE Health Care
  • CPHC Consumer Discretionary
  • Exchange
  • FATE Nasdaq
  • CPHC Nasdaq
  • Market Cap
  • FATE 108.2M
  • CPHC 102.1M
  • IPO Year
  • FATE 2013
  • CPHC 1994
  • Fundamental
  • Price
  • FATE $0.77
  • CPHC $18.49
  • Analyst Decision
  • FATE Hold
  • CPHC
  • Analyst Count
  • FATE 9
  • CPHC 0
  • Target Price
  • FATE $5.50
  • CPHC N/A
  • AVG Volume (30 Days)
  • FATE 1.6M
  • CPHC 1.6K
  • Earning Date
  • FATE 03-05-2025
  • CPHC 05-08-2025
  • Dividend Yield
  • FATE N/A
  • CPHC 1.53%
  • EPS Growth
  • FATE N/A
  • CPHC N/A
  • EPS
  • FATE N/A
  • CPHC 0.42
  • Revenue
  • FATE $13,631,000.00
  • CPHC $61,562,288.00
  • Revenue This Year
  • FATE N/A
  • CPHC N/A
  • Revenue Next Year
  • FATE N/A
  • CPHC N/A
  • P/E Ratio
  • FATE N/A
  • CPHC $44.05
  • Revenue Growth
  • FATE N/A
  • CPHC 0.20
  • 52 Week Low
  • FATE $0.74
  • CPHC $18.00
  • 52 Week High
  • FATE $7.35
  • CPHC $24.78
  • Technical
  • Relative Strength Index (RSI)
  • FATE 33.08
  • CPHC 35.86
  • Support Level
  • FATE $0.83
  • CPHC $18.00
  • Resistance Level
  • FATE $0.96
  • CPHC $18.50
  • Average True Range (ATR)
  • FATE 0.06
  • CPHC 0.20
  • MACD
  • FATE -0.00
  • CPHC -0.02
  • Stochastic Oscillator
  • FATE 11.54
  • CPHC 32.67

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About CPHC Canterbury Park Holding Corporation 'New'

Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.

Share on Social Networks: